Vaccine Development Services - Infectious Disease

Vaccine Development for Infectious Diseases

Vaccines are designed to provoke an immune response against specific biological threats through the administration of an immunogenic antigen. Consequently, the severity of future infections from such agents is either mitigated or completely avoided. Vaccines are designed to strategically place a false trigger for the immune system which in turn enables quicker and accurate response to the actual threat. Certain pathogenic viruses and bacteria that inflict infectious diseases can be vaccinated against.

Illustration of the advantages of biomaterials in vaccine design.

Fig.1 Advantages of biomaterials in vaccine design. (Gebre M. S., et al., 2021)

Emerging Technologies in Vaccine Development

mRNA Vaccines: The mRNA vaccines created to counter the COVID-19 virus outbreak illustrate the level of advancement in technology where the biological processes of our body are utilized to create viral proteins and subsequently enact an immune response. Such systems guarantee fast vaccine development and its changes for other pathogens as well.
Adjuvants: Adjuvants are compounds that produce a more exaggerated immune response to a vaccine and thus make it more useful. New adjuvants can be designed that will enable the vaccine to be more powerful and use fewer formulations of the vaccine.

Vector-based Vaccines: Vector-based vaccines are constructed on the premise of using non pathogenic viruses or viral carriers to deliver antigenic pieces to the cells that will trigger an immune response. These vaccines are applicable in Zika and Ebola viruses and many more infectious diseases are being investigated.
Systems Biology Approaches: This novel technology allows the integration of several data sets into one system which can be studied in regards to the immune response to the vaccination. These techniques allow precision in vaccine development to enhance the probabilistic rationale of predicting immunogenicity and potentially harmful effects following vaccination.

Our Services

The intricate steps involved in conceiving a vaccine for infectious diseases requires a scientific understanding, compliance with legal requirements and testing. Our company is focused on providing custom solutions for all facets related to vaccine development covering all the hurdles posed by different pathogens.

Our organization now proudly presents one-stop solutions for preclinical vaccine creation, as we have put together the structure to meet our esteemed clientele's convenience. We appreciate the necessity to simplify the development process integrating different stages effortlessly.

Preclinical Testing

Prior to clinical trials, extensive preclinical evaluation is critical to assess the safety and efficacy of the vaccine candidates. Our company performs thorough investigations through suitable models of the disease to characterizes the immune response, dose response relationships, and evaluate the possible adverse effects.

Vaccine Formulation and Optimization

Our firm practices sophisticated formulation development methods that best capitalize on the delivery and presentation of antigens to make sure that there is maximal immunogenicity and immunity retention. Such techniques also involve the use of adjuvants which are used to boost the immune response to make the vaccine more effective.

Antigen Selection and Characterization

The first critical step in vaccine development consists of determining and characterizing the most promising antigen. The sources we consider range from whole pathogens and recombinant nucleic acids to subunit antigens to guarantee the selection of the best candidate.

The field of vaccine development is constantly evolving, with emerging technologies offering promising avenues for innovation and improvement. At our company, we embrace these advancements to enhance the effectiveness and accessibility of vaccines. If our comprehensive range of services has captured your interest, we wholeheartedly urge you to reach out to us without any hesitation.

Reference

Gebre Makda S., et al. "Novel approaches for vaccine development." Cell 184.6 (2021): 1589-1603.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy